Neurology

Following is a digest of pharmacogenomics journal articles pertaining to neurology. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.


Article Citation & PubMed LinkTypeMonthSNP•its Study Summary
Guacci A et al. Phenytoin neurotoxicity in a child carrying new STXBP1 and CYP2C9 gene mutations. Seizure. 2016;34:26-8.Case Report2016-01
Patriquin MA et al. Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet. 2015;25:181–93.Systematic Review2015-10
Franco V et al. The pharmacogenomics of epilepsy. Expert Rev Neurother. 2015;15:1161-70Review2015-10
Franco V et al. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin Drug Metab Toxicol. 2015;8:1269-79.Review2015-08
Tan JC et al. Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment. J Clin Neurosci. 2015;22:1992-3.Case Report2015-08
Noai M et al. Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. Acta Neurol Scand. 2015 Jul 30 [Epub ahead of print].Retrospective Cohort2015-07
Powell G et al. Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients’ and physicians’ preferences for testing and service delivery. Br J Clin Pharmacol. 2015 Jul 3 [Epub ahead of print].Survey2015-07
Corvol J-C et al. Clinical implications of neuropharmacogenetics. Rev Neurol. 2015;171:482–97.Systematic Review2015-06
Veeravigrom M et al. Phenytoin toxicity in two-month-old Thai infant with CYP2C9 gene polymorphism – a case report. Brain Dev. 2015 May 18 [Epub ahead of print].Case Report2015-05
Greenbaum L et al. Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better uderstanding Parkinson’s Disease modifier genes. Front Neurol. 2015;6:27.Review2015-03
Kurzawski M et al. Pharmacogenetic considerations in the treatment of Parkinson’s disease. Neurodegener Dis Manag. 2015;5:27–35.Review2015-02
Chan BSH et al. Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism. Clin Toxicol (Phila). 2015;1–3.Case report2015-01
Campbell NL et al. Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. Clin Interv Aging. 2015;10:269–75.Cross-sectional study2015-01
Grey Née Cotte S et al. Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis. J Neuroimmunol. 2015;278:277–9.Retrospective cohort2015-01
Zeng T et al. Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis. Int J Dermatol. 2014 Nov 27 [Epub ahead of print].Meta-analysis2014-11
Caudle KE et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014;96:542–8.Guideline2014-11
Walker LE et al. Personalized medicine approaches in epilepsy. J Intern Med. 2014 Oct 23 [Epub ahead of print].Review2014-10
Chen Z et al. Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions. Neurology. 2014 Oct 29 [Epub ahead of print].Retrospective Observational Study2014-10
Aggarwal R et al. HLA-B(*)1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population. Hum Immunol. 2014 Oct 8 [Epub ahead of print].Case Control2014-10
Hashi S et al. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. Eur J Clin Pharmacol. 2014 Oct 18 [Epub ahead of print].PK/PD Study2014-10
Džoljic E et al. Pharmacogenetics of drug response in Parkinson’s disease. Int J Neurosci. 2014 Oct 15 [Epub ahead of print].Review2014-10
Dzolijic E et al. Pharmacogenetics of drug response in Parkinson's disease. Int J Neurosci. 2014;16:1-33.Review2014-10 
Song JS et al. Absence of HLA-B(*)1502 and HLA-A(*)3101 Alleles in 9 Korean Patients With Antiepileptic Drug-Induced Skin Rash: A Preliminary Study. Ann Lab Med. 2014;34:372-5.Retrospective cohort2014-09 
Khor AH et al. HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. Epilepsia. 2014 Sep [Epub ahead of print].Retrospective analysis2014-09 
Lee MTM et al. Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity. Public Health Genomics. 2014 Oct 21 [Epub ahead of print].Review2014-09
Khor AH-P et al. HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. Epilepsia. 2014 Sep 29 [Epub ahead of print].Meta-Analysis2014-09
Lee B et al. HLA genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: A pilot study. Pediatr Neurol. 2014;51:204-14.Pilot 2014-08
Caudle KE et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing. Clin Pharmacol Ther. 2014 Aug; [Epub ahead of print].Guidelines

 
2014-08 
Yamamoto Y et al. Individualized phenytoin therapy for pediatric Japanese epilepsy patients based on CYP2C9 and CYP2C19 genotypes. Ther Drug Monit. 2014 Aug; [Epub ahead of print].Prospective cohort study

 
2014-08 
Carlson RJ et al. Current Developments in Pharmacogenomics of Multiple Sclerosis. Cell Mol Neurobiol. 2014 Aug; [Epub ahead of print].Review

 
2014-08 
Chong KW, et al. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Arch Dis Child. 2014;99:581-4 Case-control2014-06 
Cheon M et al. Toxic epidermal necrolysis in a patient with HLA-B*5901 haplotype caused by topical and oral carbonic anhydrase inhibitors. Ann Dermatol. 2014;26:645–6.Case Report2014-05
Kulakova OG et al. Comparative pharmacogenetics of multiple sclerosis: IFN-ß versus glatiramer acetate.  Pharmacogenomics. 2014:15(5): 679-85. Perspective2014-04
Payne PW. Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct? Pharmacogenomics J. 2014 Apr; [Epub ahead of print]. Review2014-04
Viana M et al. Pharmacogenomics of episodic migraine: time has come for a step forward. Pharmacogenomics. 2014;15:541-9. Review2014-03